The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Saved in:
| Title: | The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. |
|---|---|
| Authors: | Damotte, Diane1,2,3,4 (AUTHOR), Warren, Sarah5 (AUTHOR), Arrondeau, Jennifer4,6 (AUTHOR), Boudou-Rouquette, Pascaline4,6 (AUTHOR), Mansuet-Lupo, Audrey1,2,3,4 (AUTHOR), Biton, Jérôme7 (AUTHOR), Ouakrim, Hanane1,2,3 (AUTHOR), Alifano, Marco1,2,4,8 (AUTHOR), Gervais, Claire4,6 (AUTHOR), Bellesoeur, Audrey4,6 (AUTHOR), Kramkimel, Nora4,9 (AUTHOR), Tlemsani, Camille4,6 (AUTHOR), Burroni, Barbara3 (AUTHOR), Duche, Angéline10 (AUTHOR), Letourneur, Franck10 (AUTHOR), Si, Han11 (AUTHOR), Halpin, Rebecca11 (AUTHOR), Creasy, Todd11 (AUTHOR), Herbst, Ronald11 (AUTHOR), Ren, Xing5 (AUTHOR) |
| Source: | Journal of Translational Medicine. 11/4/2019, Vol. 17 Issue 1, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
